相关实验视频

Updated: Jul 18, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

所有关于blinatumomab:对B细胞急性淋巴细胞白血病的双特异性T细胞参与免疫疗法

Reza Mirfakhraie¹, Bentolhoda Kuhestani Dehaghi², Mahmoud Dehghani Ghorbi³

¹Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hematology, transfusion and cell therapy

|August 21, 2023

概括

布利纳图莫马布为B细胞急性淋巴细胞白血病 (B-ALL) 患者提供了改善的结果,患者的残留疾病或复发/耐药性疾病最小. 虽然有效,但潜在的神经毒性和细胞因子释放综合征需要谨慎管理.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

B细胞急性淋巴细胞白血病-淋巴瘤 (B-ALL) 在儿童和成人群体中占ALL病例的很大一部分.
尽管取得了进展,但患有最小残留性疾病 (MRD) 或复发/耐药 (R/R) B-ALL的患者仍面临着不良预后.
新型疗法正在改变B-ALL治疗,包括向药物和改进的支持性护理.

研究的目的:

审查blinatumomab在治疗R/R和MRD阳性B-ALL中的疗效和功能.
讨论blinatumomab作为B-ALL的新疗法选择的好处和缺点.

主要方法:

布利纳莫马布是一种双特异性T细胞参与剂,向B细胞上的CD19和T细胞上的CD3.
它重定向细胞毒性T细胞以消除B-ALL细胞.
本综述综合了关于blinatumomab在B-ALL.治疗中的现有数据.

主要成果:

布利纳莫马布已经显示出有前途的结果,包括高水平的MRD消极性和长期存活率.
它被FDA批准用于MRD阳性或R/R B-ALL.
将blinatumomab纳入治疗方案可能会改善高风险B-ALL患者的治疗结果.

结论:

布利纳图莫马布是针对特定B-ALL患者群体的有效疗法.
关键不良事件包括神经毒性和细胞因子释放综合征.
仔细考虑其益处和风险对于优化B-ALL治疗至关重要.

关键词:

急性淋巴细胞白血病 (Acute Lymphoblastic Leukemia) 是一种急性淋巴细胞白血病.布莱纳图莫马巴姆是什么意思淋巴瘤是一种淋巴瘤.最少残留疾病的最小残留疾病.复发 / 耐火性复发 / 耐火性

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...